Insight Molecular Diagnostics Inc. Deferred Revenue
Insight Molecular Diagnostics Inc. (IMDX) had Deferred Revenue of $500.00 thousand as of 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2021-11-09
- 2021-09-30: Deferred Revenue $500.00K.
- 2021-06-30: Deferred Revenue $200.00K.
| Period end | Deferred Revenue |
|---|---|
| 2021-09-30 | $500.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $200.00K 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |